LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Dr. Louise Eisenhardt's personal notes: how she and Dr. Cushing collected data and followed patients.

    Hundley, Kelsey N / Pait, T Glenn / Rodriguez, Analiz / Day, John D

    Journal of neurosurgery

    2021  Volume 136, Issue 4, Page(s) 1173–1178

    Abstract: Dr. Louise Eisenhardt was one of the first neuropathologists and was responsible for the development of tumor diagnosis guidelines. This historical vignette reviews her previously unseen handwritten notes in which she describes methods used by her and Dr. ...

    Abstract Dr. Louise Eisenhardt was one of the first neuropathologists and was responsible for the development of tumor diagnosis guidelines. This historical vignette reviews her previously unseen handwritten notes in which she describes methods used by her and Dr. Harvey Cushing to obtain patient follow-up data for their Brain Tumor Registry. Her description spans 50 years, using "every possible clue to be jumped upon in [their] clinical records and correspondence." Their follow-up was divided into two periods: early follow-up (1912-1932) and registry (1933-1961). During early follow-up, patients were asked to write to them on the anniversary of their operation. The foundation of the registry necessitated the use of "considerable effort on [their] part to gather up old threads" including renewed contact with patients after 15-20 years. Methods of follow-up included continued verbal and written correspondence with patients and "strong-arm methods," including use of the Fuller Brush man and the exhumation of a body. Drs. Eisenhardt and Cushing believed "every case was important in adding to our collective knowledge of various types of tumors particularly in relationship to life expectancies and suggesting improvement in surgical treatments." Dr. Eisenhardt's meticulous record keeping allows for insights into the first known outcomes-related tumor registry in neurosurgery.
    MeSH term(s) Anniversaries and Special Events ; Brain Neoplasms/surgery ; Female ; History, 20th Century ; Humans ; Neurosurgery/history ; Neurosurgical Procedures ; Registries
    Language English
    Publishing date 2021-09-24
    Publishing country United States
    Document type Historical Article ; Journal Article
    ZDB-ID 3089-2
    ISSN 1933-0693 ; 0022-3085
    ISSN (online) 1933-0693
    ISSN 0022-3085
    DOI 10.3171/2021.4.JNS201086
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Bortezomib-Associated Optic Atrophy in Two Patients With Multiple Myeloma.

    Chacko, Joseph G / Behbehani, Raed / Hundley, Kelsey N / Al-Fanek, Yazan

    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society

    2018  Volume 38, Issue 4, Page(s) 473–475

    MeSH term(s) Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Bortezomib/adverse effects ; Bortezomib/therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Optic Atrophy/chemically induced ; Optic Atrophy/diagnosis ; Optic Disk/pathology ; Tomography, Optical Coherence/methods ; Visual Acuity
    Chemical Substances Antineoplastic Agents ; Bortezomib (69G8BD63PP)
    Language English
    Publishing date 2018-05-10
    Publishing country United States
    Document type Case Reports ; Letter
    ZDB-ID 1189901-3
    ISSN 1536-5166 ; 1070-8022
    ISSN (online) 1536-5166
    ISSN 1070-8022
    DOI 10.1097/WNO.0000000000000657
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Decompression of Cavernous Sinus for Trigeminal Neuropathic Pain From Perineural Spread of Tumor: 2-Dimensional Operative Video.

    Morris, Thomas W / Hundley, Kelsey N / Thomas, Kevin O / Lockhart, Elijah C / Rodriguez, Analiz / Day, John D

    Operative neurosurgery (Hagerstown, Md.)

    2020  Volume 19, Issue 3, Page(s) E304–E305

    Abstract: Head and neck malignancies with perineural spread are rare. Patients can present with neuropathic pain and cranial nerve palsies.1 Skull base approaches for surgical decompression are a consideration for patients to provide symptom relief.2 We ... ...

    Abstract Head and neck malignancies with perineural spread are rare. Patients can present with neuropathic pain and cranial nerve palsies.1 Skull base approaches for surgical decompression are a consideration for patients to provide symptom relief.2 We demonstrate a frontotemporal extradural approach for a patient with worsening visual symptoms and refractory neuropathic pain in the V1, V2, and V3 distributions and briefly review the relevant anatomy.3-7  A 41-yr-old female with a poorly differentiated carcinoma of the head and neck with an infiltration of the cavernous sinus and perineural spread along the trigeminal nerve presented with severe neuropathic facial pain and anesthesia. She had previously undergone radiosurgery. Magnetic resonance imaging (MRI) demonstrated an interval increase in perineural disease within the cavernous sinus with extension intradurally. Her pain was medically refractory. A 2-dimensional intraoperative video illustrates the microsurgical decompression of her perineural invasion along the skull base as a palliative procedure. The patient recovered well postoperatively and had a symptomatic improvement in her pain and visual symptoms. Her preoperative facial numbness persisted postoperatively as expected. Postoperative imaging demonstrates a gross total resection of the intradural component of the tumor with decompression and expected expansion of the cavernous sinus. Because of the retrospective nature of this report, informed consent was not required. Images within the video have been reproduced from Fukuda et al4 with permission from © Georg Thieme Verlag KG; and Matsuo et al5 by permission of the Congress of Neurological Surgeons.
    MeSH term(s) Adult ; Cavernous Sinus/diagnostic imaging ; Cavernous Sinus/surgery ; Decompression ; Female ; Head and Neck Neoplasms ; Humans ; Neuralgia ; Retrospective Studies
    Language English
    Publishing date 2020-03-08
    Publishing country United States
    Document type Case Reports ; Journal Article ; Video-Audio Media
    ZDB-ID 2767575-0
    ISSN 2332-4260 ; 2332-4252
    ISSN (online) 2332-4260
    ISSN 2332-4252
    DOI 10.1093/ons/opaa033
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for Glioblastoma.

    Reed, Megan R / Lyle, A Geoffrey / De Loose, Annick / Maddukuri, Leena / Learned, Katrina / Beale, Holly C / Kephart, Ellen T / Cheney, Allison / van den Bout, Anouk / Lee, Madison P / Hundley, Kelsey N / Smith, Ashley M / DesRochers, Teresa M / Vibat, Cecile Rose T / Gokden, Murat / Salama, Sofie / Wardell, Christopher P / Eoff, Robert L / Vaske, Olena M /
    Rodriguez, Analiz

    Cells

    2021  Volume 10, Issue 12

    Abstract: Li Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome caused by germline mutations in TP53. TP53 is the most common mutated gene in human cancer, occurring in 30-50% of glioblastomas (GBM). Here, we highlight a precision medicine ... ...

    Abstract Li Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome caused by germline mutations in TP53. TP53 is the most common mutated gene in human cancer, occurring in 30-50% of glioblastomas (GBM). Here, we highlight a precision medicine platform to identify potential targets for a GBM patient with LFS. We used a comparative transcriptomics approach to identify genes that are uniquely overexpressed in the LFS GBM patient relative to a cancer compendium of 12,747 tumor RNA sequencing data sets, including 200 GBMs. STAT1 and STAT2 were identified as being significantly overexpressed in the LFS patient, indicating ruxolitinib, a Janus kinase 1 and 2 inhibitors, as a potential therapy. The LFS patient had the highest level of STAT1 and STAT2 expression in an institutional high-grade glioma cohort of 45 patients, further supporting the cancer compendium results. To empirically validate the comparative transcriptomics pipeline, we used a combination of adherent and organoid cell culture techniques, including ex vivo patient-derived organoids (PDOs) from four patient-derived cell lines, including the LFS patient. STAT1 and STAT2 expression levels in the four patient-derived cells correlated with levels identified in the respective parent tumors. In both adherent and organoid cultures, cells from the LFS patient were among the most sensitive to ruxolitinib compared to patient-derived cells with lower STAT1 and STAT2 expression levels. A spheroid-based drug screening assay (3D-PREDICT) was performed and used to identify further therapeutic targets. Two targeted therapies were selected for the patient of interest and resulted in radiographic disease stability. This manuscript supports the use of comparative transcriptomics to identify personalized therapeutic targets in a functional precision medicine platform for malignant brain tumors.
    MeSH term(s) Adolescent ; Adult ; Child ; Female ; Gene Expression Regulation, Neoplastic ; Germ-Line Mutation/genetics ; Glioblastoma/complications ; Glioblastoma/genetics ; Glioblastoma/pathology ; Humans ; Janus Kinase 1/antagonists & inhibitors ; Janus Kinase 1/genetics ; Janus Kinase 2/antagonists & inhibitors ; Janus Kinase 2/genetics ; Li-Fraumeni Syndrome/complications ; Li-Fraumeni Syndrome/genetics ; Li-Fraumeni Syndrome/pathology ; Male ; Nitriles/pharmacology ; Organoids/metabolism ; Precision Medicine ; Pyrazoles/pharmacology ; Pyrimidines/pharmacology ; RNA-Seq ; STAT1 Transcription Factor/genetics ; STAT2 Transcription Factor/genetics ; Transcriptome/genetics ; Young Adult
    Chemical Substances Nitriles ; Pyrazoles ; Pyrimidines ; STAT1 Transcription Factor ; STAT1 protein, human ; STAT2 Transcription Factor ; STAT2 protein, human ; ruxolitinib (82S8X8XX8H) ; Janus Kinase 1 (EC 2.7.10.2) ; Janus Kinase 2 (EC 2.7.10.2)
    Language English
    Publishing date 2021-12-02
    Publishing country Switzerland
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2661518-6
    ISSN 2073-4409 ; 2073-4409
    ISSN (online) 2073-4409
    ISSN 2073-4409
    DOI 10.3390/cells10123400
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top